Osimertinib is a targeted therapy, belonging to the third-generation EGFR (epidermal growth factor receptor) tyrosine kinase inhibitors.
Side effects requiring immediate medical attention for Osimertinib
If any of the following side effects occur while taking Osimertinib, seek immediate medical attention:
1. More common side effects
(1) Anxiety, cough, dizziness, lightheadedness or fainting, changes in eyes or vision, rapid, throbbing or irregular heartbeat, pain in the chest, groin or legs, especially the calves;
(2) Pain, redness or swelling in the arms or legs, slurred speech, sudden loss of coordination, sudden severe headache, sudden severe weakness or numbness in the arms or legs, difficulty breathing.
2. Less common side effects:
Blurred vision, chills, fever, malaise or feeling sick, inability to speak, seizures, sneezing, sore throat, sudden severe weakness on one side of the body, temporary blindness, thickened bronchial secretions.
3. Rare side effects:
Chest pain or tightness, red, inflamed, or painful eyes, headache, swollen or painful glands, abnormal bleeding or bruising.
4. Side effects of unknown frequency:
Blistering, peeling, or loose skin, diarrhea, itching, joint or muscle pain, red lesions on the skin (often with a purple center), sore throat, sores, ulcers, or white spots on the mouth or lips, unusual fatigue or weakness.
Mild Side Effects of Osimertinib
If any of the following side effects persist or bother you while taking osimertinib, or if you have any questions about these side effects, consult a healthcare professional:
Back pain; nail (fingernails or toenails) changes, including brittleness, inflammation, pain, redness, tenderness, separation from the nail bed, or nail loss; constipation; decreased appetite; nausea; rash or dry skin; swelling or inflammation of the mouth.
Side Effects of Osimertinib for Healthcare Professionals' Reference
1. Hematologic Adverse Reactions
(1) Very Common
Lymphopenia (63%), Thrombocytopenia (54%), Anemia (44%), Neutropenia (33%).
2. Gastrointestinal Reactions
(1) Very Common
Diarrhea (42%), Nausea (17%), Decreased Appetite (16%), Constipation (15%), Stomatitis (12%), Vomiting (11%).
3. Skin Reactions
(1) Very Common
Rash (e.g., generalized rash, erythema, macules, papules, pustules), erythema, folliculitis, acne, dermatitis, acneiform dermatitis (58%); dry skin (e.g., eczema, fissured skin, xerosis) (36%); nail toxicity (e.g., nail and nail bed abnormalities, nail bed inflammation, nail bed tenderness, nail discoloration, nail dystrophy, nail infection, nail longitudinal ridges, nail breakage, onycholysis, nail shedding, paronychia) (35%); pruritus (17%).
(2) Post-Marketing Reports
Erythema multiforme (EMM), Stevens-Johnson syndrome (SJS), cutaneous vasculitis.
4. Metabolic Abnormalities
(1) Very Common
Hyponatremia (26%), Hypermagnesemia (20%).
5. Ocular Reactions
(1) Very Common
Ocular abnormalities (e.g., dry eye, blurred vision, keratitis, cataracts, eye irritation, blepharitis, eye pain, increased tearing, vitreous opacity) (18%).
(2) Uncommon
Other ocular toxicities.
6. Respiratory Reactions
(1) Very Common
Cough (17%), dyspnea (13%).
(2) Common
Interstitial lung disease/pneumonia, pneumonia.
7. Musculoskeletal Reactions
(1) Very Common
Back pain (13%).
8. Nervous System Reactions
(1) Very Common
Headache (10%).
(2) Common
Cerebrovascular accident/cerebral hemorrhage.
9. Cardiovascular Reactions
(1) Common
Cardiomyopathy, venous thromboembolism (including deep vein thrombosis, jugular vein thrombosis, pulmonary embolism).
(2) Incidence not reported
QTc interval prolongation.
10. Other reactions
(1) Very common
Fatigue (22%).
Note: Osimertinib's very common adverse reactions (10% and above); common adverse reactions (1%-10%); uncommon adverse reactions (0.1%-1%).
